Dannielle Appelhans - Jan 31, 2023 Form 4 Insider Report for Rubius Therapeutics, Inc. (RUBY)

Role
CEO and President
Signature
/s/ Jennifer Kamocsay, attorney-in-fact
Stock symbol
RUBY
Transactions as of
Jan 31, 2023
Transactions value $
-$970
Form type
4
Date filed
2/1/2023, 08:40 PM
Previous filing
Aug 12, 2022
Next filing
Feb 27, 2023

Transactions Table

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Ownership Footnotes
transaction RUBY Common Stock Options Exercise +7.5K +110.9% 14.3K Jan 31, 2023 Direct F1
transaction RUBY Common Stock Sale -$970 -3.88K -27.19% $0.25* 10.4K Feb 1, 2023 Direct F2

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Underlying Class Amount Exercise Price Ownership Footnotes
transaction RUBY Restricted Stock Units Options Exercise $0 -7.5K -25% $0.00 22.5K Jan 31, 2023 Common Stock 7.5K Direct F1, F3
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id Content
F1 Each restricted stock unit represents a contingent right to receive one share of the Issuer's common stock.
F2 Represents the number of shares required to be sold to cover the statutory tax withholding obligations in connection with the vesting of the restricted stock units listed in Table II. This sale is mandated by the Issuer's election under its equity incentive plans to require the satisfaction of minimum statutory tax withholding obligations to be funded by a "sell to cover" transaction and does not represent a discretionary sale by the reporting person.
F3 The shares underlying the restricted stock units vest in four equal annual installments beginning on January 31, 2023.

Remarks:

Exhibit List - Exhibit 24 - Power of Attorney